Commonwealth Serum Laboratories
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:abbreviation |
gptkb:CSL
|
| gptkbp:country |
gptkb:Australia
|
| gptkbp:founded |
1916
|
| gptkbp:founder |
gptkb:Government_of_India
|
| gptkbp:headquarters_location |
gptkb:Melbourne
|
| https://www.w3.org/2000/01/rdf-schema#label |
Commonwealth Serum Laboratories
|
| gptkbp:industry |
gptkb:biotechnology
pharmaceuticals |
| gptkbp:notable_for |
COVID-19 vaccine production
development of medical antivenoms |
| gptkbp:notableEvent |
privatization in 1994
|
| gptkbp:notableProduct |
vaccines
antivenoms blood plasma products |
| gptkbp:parentOrganization |
gptkb:CSL_Limited
|
| gptkbp:publiclyTraded |
gptkb:ASX:_CSL
|
| gptkbp:subsidiary |
gptkb:CSL_Behring
gptkb:Seqirus |
| gptkbp:website |
https://www.csl.com.au/
|
| gptkbp:bfsParent |
gptkb:CSL
|
| gptkbp:bfsLayer |
5
|